CTLA4 and neoplasm: Consequently, inhibiting these receptors with antibodies has been shown to enhance anti-tumor T cell activity [56] and several clinical trials are underway to evaluate the efficacy of anti-CTLA-4 and anti-PD-1 therapies in BCBMs (Table 1).